Last $8.57 USD
Change Today -0.35 / -3.92%
Volume 10.9M
NVAX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

novavax inc (NVAX) Snapshot

Open
$8.85
Previous Close
$8.92
Day High
$8.89
Day Low
$8.38
52 Week High
02/23/15 - $9.83
52 Week Low
04/15/14 - $3.34
Market Cap
2.1B
Average Volume 10 Days
5.8M
EPS TTM
$-0.36
Shares Outstanding
239.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVAVAX INC (NVAX)

novavax inc (NVAX) Related Businessweek News

No Related Businessweek News Found

novavax inc (NVAX) Details

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing recombinant protein nanoparticle vaccines and adjuvants. The company’s vaccine technology platform is based on proprietary recombinant nanoparticle vaccine technology that includes virus-like particles vaccines and protein nanoparticle vaccines. Its vaccine candidates target seasonal influenza, pandemic influenza, and respiratory syncytial virus. The company also develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. has a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

308 Employees
Last Reported Date: 02/27/15
Founded in 1987

novavax inc (NVAX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $448.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $156.3K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $371.9K
Senior Vice President of Global Manufacturing...
Total Annual Compensation: $284.5K
Compensation as of Fiscal Year 2013.

novavax inc (NVAX) Key Developments

Novavax, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Novavax, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $6,724,000 compared to $8,748,000 a year ago. Loss from operations was $31,664,000 compared to $14,253,000 a year ago. Loss from operations before income tax expense was $31,546,000 compared to $14,051,000 a year ago. Net loss was $31,546,000 compared to $14,054,000 a year ago. Basic and diluted net loss per share was $0.13 compared to $0.07 a year ago. The increase in net loss is primarily the result of increased R&D expenses related to the successful RSV F vaccine program and the initiation of 3 RSV clinical trials in the third and fourth quarter of 2014. The 23% decrease in revenue was primarily related to revenues recognized under past agreement for the fourth quarter of 2013 related to the initiation of the Phase II RSV trial in women of childbearing age. For the full year, the company reported revenue of $30,659,000 compared to $20,915,000 a year ago. Loss from operations was $83,691,000 compared to $52,434,000 a year ago. Loss from operations before income tax expense was $82,947,000 compared to $51,958,000 a year ago. Net loss was $82,947,000 compared to $51,983,000 a year ago. Basic and diluted net loss per share was $0.37 compared to $0.31 a year ago. Net cash used in operating activities was $67.0 million, compared to $45.4 million for 2013. The increase in full year revenue results from the 2014 Phase I/II clinical trial of the H7N9 pandemic vaccine candidate and activities related to the preparation and initiation of the Phase II clinical trial of the quadrivalent seasonal influenza vaccine.

Novavax, Inc. to Report Q4, 2014 Results on Feb 26, 2015

Novavax, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 26, 2015

Novavax, Inc., Q4 2014 Earnings Call, Feb 26, 2015

Novavax, Inc., Q4 2014 Earnings Call, Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVAX:US $8.57 USD -0.35

NVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $26.37 USD -0.76
Dynavax Technologies Corp $19.72 USD +0.91
Inovio Pharmaceuticals Inc $7.05 USD -0.12
Progenics Pharmaceuticals Inc $6.78 USD +0.13
ZIOPHARM Oncology Inc $12.49 USD +0.70
View Industry Companies
 

Industry Analysis

NVAX

Industry Average

Valuation NVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 69.4x
Price/Book 9.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 64.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVAVAX INC, please visit www.novavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.